Article
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
PLoS genetics - 1 Jan 2023
Ferrando Lorenzo, Vingiani Andrea, Garuti Anna, Vernieri Claudio, Belfiore Antonino, Agnelli Luca, Dagrada Gianpaolo, Ivanoiu Diana, Bonizzi Giuseppina, Munzone Elisabetta, Lippolis Luana, Dameri Martina, Ravera Francesco, Colleoni Marco, Viale Giuseppe, Magnani Luca, Ballestrero Alberto, Zoppoli Gabriele, Pruneri Giancarlo
Abstract excerpt
BACKGROUND: Previous studies have provided a comprehensive picture of genomic alterations in primary and metastatic Hormone Receptor (HR)-positive, Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer (HR+ HER2- BC). However, the evolution of the genomic landscape of HR+ HER2- BC during adjuvant endocrine therapies (ETs) remains poorly investigated. METHODS AND FINDINGS: We performed a genomic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.